Objective: To determine the association between synaptic functioning as measured via neurogranin in CSF and cognition relative to established Alzheimer disease (AD) biomarkers in neurologically healthy older adults.
normal aging remains unknown. 7, 10 In AD, neurogranin is depleted in the brain, elevated in CSF, and associated with tau and (to a lesser degree) amyloid pathology and poorer cognitive performance. [11] [12] [13] [14] [15] Higher baseline CSF neurogranin is associated with faster declines in cognition, cortical glucose metabolism, and hippocampal volumes in individuals with mild cognitive impairment and AD. 16 While there are differences in neurogranin concentrations between healthy individuals and patients with AD, no clinical studies have examined neurogranin's relationship to cognition and markers of AD development in aging.
We aimed to address this major gap by characterizing the association between neurogranin and memory abilities in relation to established AD biomarkers among clinically normal older adults. We hypothesized that higher CSF neurogranin would be associated with older age and poorer memory performance. In addition, given that AD neuropathology develops early in aging, we hypothesized that AD-related biomarkers would interact with neurogranin to confer greater risk of reduced memory performance.
METHODS Participants. We studied 132 communitydwelling older adults cross-sectionally from the Wisconsin Registry for Alzheimer's Prevention study and the Wisconsin Alzheimer's Disease Research Center who completed neuroimaging, lumbar puncture, blood draw, and memory testing. Inclusion criteria included (1) neuropsychological functioning within normative standards determined via a comprehensive battery and consensus review, 17 (2) no history of neurologic or major psychiatric disease, (3) no history of major medical illness, and (4) no MRI contraindications. All participants with available data were included in analyses; all participants had complete data on the major variable of interest (CSF neurogranin). We selected the study group to represent healthy middle-aged to older adults with and without parents with lateonset AD. Therefore, the current sample was enriched for family history of AD and the genetic AD risk factor APOE e4 (table 1) . We defined a parental history of AD by a validated interview 18 or by confirmed AD at autopsy as reviewed by a multidisciplinary diagnostic consensus. Participants were determined to have a negative parental history of AD if the participant's father survived to .70 years and mother to .75 years without a diagnosis of dementia or cognitive decline 17 per comprehensive medical interviews.
Standard protocol approvals, registrations, and patient consents. All study procedures were approved by the University of Wisconsin Health Sciences institutional review board in accordance with US federal regulations and the Helsinki declaration. All participants provided written informed consent.
CSF collection and analysis. CSF samples were collected in the morning after a 12-hour fasting period. Approximately 22 mL of CSF were tapped and inverted to avoid possible gradients, gently mixed, and centrifuged at 2,000g for 10 minutes before being frozen in 0.5 mL aliquots and stored at 2808C.
CSF samples were analyzed for phosphorylated tau (p-tau), total tau (t-tau), and the 42 amino acid form of b-amyloid (Ab42) via standard commercially available ELISA (INNOTEST assays; Fujiurebio, Ghent, Belgium). 19 Details regarding CSF neurogranin analysis are given elsewhere 5, 13 ; in brief, we utilized the monoclonal anti-Ng7 antibody Ng7 and the primary rabbit anti-Ng antibody (Upstate) in a sandwich ELISA format. Boardcertified laboratory technicians blinded to participant clinical history performed analyses per protocols approved by the Swedish Board of Accreditation and Conformity Assessment using one batch of reagents (intra-assay coefficient of variation ,10%).
MRI. Participants underwent imaging on a GE (Fairfield, CT)
3T MR750 system equipped with an 8-channel head coil and parallel imaging (array coil spatial sensitivity encoding [ASSET] Neuropsychological testing. Memory. Given that neurogranin shows increased concentrations in the hippocampi, our primary outcome of interest was delayed recall performances assessed via the Rey Auditory Verbal Learning Test (AVLT). 20 The AVLT consists of a 15-item word list that participants are asked to immediately recall across 5 learning trials. Participants are then presented an interference trial of a novel 15-item word list before freely recalling the original list. After a 20-minute delay, participants are again asked to recall the original word list; this delayed recall score was our outcome of interest. Other cognitive domains. We additionally examined other cognitive domains to determine the specificity of the relationship between neurogranin and memory. The Wechsler Adult Intelligence Scale, 3rd edition (WAIS-III), Symbol Digit Coding, was given to measure processing speed. 21 WAIS-III Digit Span forward and backward performances (longest span) were used as measures of echoic attention and working memory. Finally, the Boston Naming Test, a 60-item confrontation naming task, was administered to assess semantic retrieval. 22 Statistical analyses. We conducted Spearman rho (r) rank correlations or Wilcoxon/Kruskal-Wallis rank sum tests to characterize relationships between neurogranin, demographics, AD-related biomarkers, and cognition. Given that prior published works examining neurogranin have primarily utilized Spearman rho associations, we opted to report these to be comparable with previous results. Plotting the relationship between neurogranin and delayed recall evidenced nonlinear curvature. Therefore, we additionally conducted regression models testing for polynomic effects ). Models examining relationships with memory performances were additionally adjusted for sex (utilizing age-corrected scores) and hippocampal models for age, sex, and total gray matter volume. To increase interpretation of polynomic effects, independent variables in the models were centered to the mean; therefore, the linear measure represents the linear change in neurogranin at the means of all other predictors on the outcome, while the polynomic parameter represents curvature of the regression line. In all analyses, missing data were minimal and excluded pairwise when necessary.
We additionally examined the independent association between neurogranin and memory performance in relation to the AD-related biomarkers and AD risk factors (APOE e4 status, AD family history), and tested whether the magnitude of the association between neurogranin with memory depended on the level of AD-related biomarkers (interaction terms). Finally, to increase interpretation and help describe the clinical significance of the observed polynomic effects between neurogranin and delayed recall, we converted neurogranin into tertiles. Table 1 presents descriptive statistics of our study sample. Notably, 72% of participants had a first-degree relative with AD and about one-third carried the APOE e4 risk allele, though participants were intact on a global cognitive screener (median Mini-Mental State Examination 30) and performed above average on a measure of delayed recall (AVLT scaled score 5 11). CSF neurogranin concentrations were slightly skewed (Shapiro-Wilk W 5 0.86, p , 0.01). Higher levels of neurogranin were associated with older age (r 5 0.20, p 5 0.02), though no polynomic relationships with age were observed (neurogranin The quadratic relationship between neurogranin and memory performance remained significant in individual models or a combined model adjusting for Ab42, t-tau, p-tau, hippocampal volumes, APOE e4 status, or family history of AD, and none of the Table 2 CSF neurogranin is associated with phosphorylated and total tau and hippocampal volumes but not amyloid in neurologically normal older adults evidenced 5 data points of individuals with high CSF neurogranin (.1,000 pg/mL) and high memory performance that appeared to be contributing to the quadratic line curvature. Given that neurogranin is a novel in vivo clinical biomarker and polynomic effects have not been reported previously, we further explored this relationship. We excluded the 5, refit the model, and found that the quadratic relationship was no longer significant, though a significant negative, linear effect between CSF neurogranin and delayed recall remained (adjusting for age, sex, AD-related biomarkers, APOE e4, and AD family history) (neurogranin CSF neurogranin is the only CNS marker associated with delayed recall performance among aging adults
RESULTS
Analyses adjusted for age. 95% Confidence intervals (CIs) calculated via bootstrapping (100 samples). b-Amyloid, total tau, phosphorylated tau (p-tau), and neurogranin represent CSF concentrations. Nonetheless, when all participants were categorized into tertiles, neurogranin tertiles were associated with delayed recall adjusting for age and sex (F 5 5.8, p 5 0.004), such that individuals with the lowest concentrations of CSF neurogranin demonstrated significantly better delayed recall performances compared to those with medium or high levels (ps , 0.03), the latter of which did not differ from one another (p 5 0.99) (figure 3). CSF neurogranin was not associated with echoic attention (r 5 0.005), working memory (r 5 0.008), or semantic retrieval (r 5 20.17) (ps . 0.05).
DISCUSSION As an indicator of synaptic physiology, CSF neurogranin was associated with age, hippocampal volumes, and tau, but was the only CNS marker linked to memory performance in clinically normal older adults. In addition, though processing speed was associated with neurogranin, this relationship was not independent of other CNS markers (i.e., t-tau and p-tau). Given that processing speed is a highly sensitive but nonspecific measure of brain functioning, the relationship between neurogranin and speed may reflect more global abilities that are also detected by the other CNS markers. These findings suggest that (1) age-related synaptic dynamics are highly sensitive to cognitive functioning (especially subtle memory abilities); (2) synaptic dysfunction may potentially precede, act synergistically, or even independently from early AD pathogenesis; and (3) monitoring synaptic status may be valid marker of brain functioning in clinically normal older adults. Though previous works have demonstrated alterations in neurogranin concentrations in patients with AD compared to healthy individuals, 14 ours is among the first to closely characterize neurogranin in cognitively normal older adults, including the polynomic nature of the relationship, and extend its association with cognition beyond brief screeners. Our findings are in adults with elevated risk for AD, limiting some generalizability of the effects; however, the independence of the association between neurogranin and memory from AD-specific biomarkers supports the potential application of synaptic protein markers to objectively monitor brain wellness even in clinically normal aging.
Though neurogranin was the most sensitive marker of delayed recall, the nature of the effect may be nuanced. We found a quadratic relationship between neurogranin and memory that was driven by a small subset of individuals (n 5 5) with high CSF neurogranin and high memory scores. Yet, even when these outlying individuals were included in analyses, overall low concentrations of CSF neurogranin were associated with better memory performances. Although the study design does not allow for conclusions regarding causality, it is tempting to speculate that low CSF concentrations of neurogranin reflect higher neurogranin availability in synapses. In the presence of NMDA-related calcium influxes, neurogranin releases calmodulin, freeing it to activate downstream protein kinase C pathways. Ultimately, these pathways increase AMPA receptor insertion, subsequently enhancing LTP. That is, higher concentrations of neurogranin sequester larger amounts of available calmodulin in the synapse, lowering the basal neuronal activity threshold needed to induce LTP and learning. 23 Conversely, a subset of individuals with the highest CSF neurogranin concentrations also demonstrated high memory performance. Given that this was not necessarily expected and the novelty of neurogranin as an in vivo clinical biomarker, interpretation of this finding would be speculative at this point. The small subset of outlying neurogranin concentrations (.1,000 pg/mL) may represent spurious Figure 3 Low CSF neurogranin is associated with better delayed recall performance in aging adults
Delayed recall scaled score is age-adjusted (mean 10, SD 3).
assay-related variability or biologically relevant information. Future studies are needed to replicate and clarify the polynomic nature of our findings. Nonetheless, CSF neurogranin was the only marker sensitive to clinical memory performance. Given that neurogranin is concentrated in the hippocampi and the hippocampi are strongly linked to memory abilities, 7 CSF neurogranin may reflect hippocampal-related plasticity processes important to learning and recall in our older adults. In contrast, hippocampal volumes were not associated with memory scores, suggesting that more nuanced hippocampal functioning subtleties may be captured by neurogranin.
Regarding its association with other markers of CNS function, we found that neurogranin was more strongly associated with CSF tau proteins and hippocampal structure than amyloid concentrations, which is consistent with recent clinical neurogranin literature in AD. Though some studies evidence a significant link between neurogranin and amyloid levels in both the brain and CSF among individuals with AD-related impairment, these relationships are consistently smaller than those observed between neurogranin and tau. 12, 13, 24 In addition, several studies, particularly those examining earlier stages of AD development, did not identify a significant relationship between neurogranin and amyloid concentrations at all.
11,25
Similarly, we found that neurogranin was not associated with and independently predicted memory beyond APOE e4 status or family history of AD, both of which are associated with greater amyloid deposition. 26 Though longitudinal studies are needed, taken together these findings suggest that the relationship between neurogranin and amyloid may be distinct and only become meaningful later in disease or at an elevated threshold of amyloid aggregation. That is, though amyloid accumulates with age, it may only interfere with or relate to neurogranin functioning once it has reached pathologic levels. This may suggest that synaptic proteins represent the broader neurologic aging spectrum not necessarily specific to AD development (i.e., aging does not equate AD).
On the other hand, neurogranin was strongly associated with p-tau and t-tau, as well as hippocampal volumes, though interactions with these markers did not moderate its relationship with memory performance. These results are also consistent with the previous studies demonstrating moderate to large effect sizes between neurogranin and tau, and hippocampal-specific changes in neurogranin with age, and may point to early concurrent aging processes. 6, [11] [12] [13] 16, 25 Though commonly considered markers of AD-related pathogenesis, tau aggregation and hippocampal atrophy manifest in early aging (i.e., 20s-30s). 27 Neurogranin may also be such a fluid metric of the broader neural aging process. These data are also complementary to recent work by Portelius et al. 16 demonstrating a relationship between high baseline CSF neurogranin and increased rapidity of cognitive, hippocampal, and cortical metabolic declines in healthy individuals and those with ADrelated impairment across time, suggesting that the neurogranin relationships observed here have high clinical relevance for subsequent disease development. However, Portelius et al. did not find an association between baseline neurogranin and performance on global cognitive screeners. Our data suggest that the relationship between neurogranin and cognition is more nuanced and perhaps specific to memory abilities. We also demonstrate that the relationship between cognition and neurogranin extends into asymptomatic individuals, though perhaps disrupted baseline neurogranin affects cognition globally given time. Continued characterization of how neurogranin and other age-sensitive markers develop, potentially interact, and change with time will be critical to our understanding of age-related cognitive decline and neurodegeneration.
One major limitation of our work is the crosssectional design. We cannot discern age-related changes in synapse-related memory abilities vs premorbid relationships. Given that we posit these synaptic functions to be dynamic with aging and to directly affect cognitive and behavioral abilities, future work utilizing longitudinal designs and experimental behavioral manipulation are needed to determine directionality of these relationships. Nonetheless, ours are the first data beginning to parse out the role of neurogranin and cognition in clinically normal older adults and lay a foundation for future synaptic aging work. In addition, our participants have overrepresented family histories of AD; therefore, the generalizability of our results may be attenuated. However, it is notable that even given the increased risk of AD, we did not observe significant relationships between neurogranin and amyloid, AD family history, or APOE e4, suggesting that preclinical AD was at least not the sole driver of our observed effects.
Markers sensitive to early clinical change in age-related brain health are needed to track and identify at-risk individuals who warrant preventative and early intervention. Integrity of synaptic functioning, and neurogranin specifically, may represent one such marker that can be used to objectively monitor clinically meaningful brain development. Given that synaptic dynamics are plastic with age and experience, further work characterizing synapse development under normal and pathologic conditions may help identify targets for intervention and be a relevant metric of interest for future clinical trials.
